Overview

Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-01-11

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to compare the efficacy and safety of EG12014 with Herceptin as neoadjuvant treatment for 12 weeks, followed by surgery and subsequent EG12014 or Herceptin adjuvant treatment for up to 12 months.

Phase:

Phase 3

Details

Lead Sponsor:

EirGenix, Inc.

Treatments:

Paclitaxel
Trastuzumab